Browse studies

Find your next paid study

5 recruiting studies matching your filters

AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER

The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). …

Intestinal NeoplasmsGastrointestinal NeoplasmsDigestive System Neoplasms+7 more

An Open-label Multicenter Phase 1b-2 Study of Elacestrant in Combination With Abemaciclib in Women and Men With Brain Metastasis From Estrogen Receptor Positive, HER-2 Negative Breast Cancer

This is a multi-site, global, open-label study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain m…

Breast NeoplasmsBrain NeoplasmsNeoplasms by Site+5 more

Estimated

~$10 – $8,750

Stemline Therapeutics, Inc.NCT05386108

Phase 1

Phase 1 Trial of Engineered HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumo…

Neoplasms, BrainGlioblastoma MultiformeGlioblastoma of Cerebellum+30 more

Estimated

~$10 – $6,250

Phase 1

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects With Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001)

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in co…

Advanced Solid TumorsGenital Neoplasm, FemaleUrogenital Neoplasms+11 more

Estimated

~$10 – $8,750

Marengo Therapeutics, Inc.NCT05592626

Phase 4

Usefulness of Tumor Heterogeneity Assessment in Patients With MCRPC Undergoing Radioligand Therapy With 177LU-PSMA-617 Using Serial 18F-DCFPYL, 18F-FDG and 18F-Fluciclovine PET/CT Predicting Clinical Outcome

This a single-center, prospective, exploratory study. Patients with metastatic castration-resistant prostate cancer (mCRPC) scheduled to undergo Lutetium label…

Prostatic NeoplasmsProstatic Neoplasms, Castration-ResistantMetastatic Prostate Cancer+8 more

Estimated

~$10 – $7,500

VA Greater Los Angeles Healthcare SystemNCT06706921